Skip to main content
Metagenomi, Inc. logo

Metagenomi, Inc. — Investor Relations & Filings

Ticker · MGX ISIN · US59102M1045 US Professional, scientific and technical activities
Open in API
Filings indexed 124 across all filing types
Latest filing 2024-05-14 Earnings Release
Country US United States of America
Listing US MGX

About Metagenomi, Inc.

https://metagenomi.co/

Metagenomi, Inc. is a genetic medicines company that develops curative therapeutics using its proprietary genome editing toolbox. The company's approach is founded on metagenomics, the study of genetic material recovered from natural environments, to discover and engineer novel gene editing systems. Its wholly-owned toolbox is designed to be capable of correcting various types of genetic mutations through site-specific deletion, integration, and correction. Metagenomi leverages high-throughput screening and AI-based cloud computing to expand its portfolio of editing technologies, focusing on disease indications with well-understood biology and clear clinical development pathways.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 14, 2024, by Metagenomi, Inc. It announces the company's financial results for the quarter ended March 31, 2024, and includes a press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2). The text explicitly states that the press release is being furnished as part of the current report and that the information is not "filed" for certain regulatory purposes. The key content is the announcement of quarterly financial results, which aligns with an Earnings Release (ER). The document length is 4241 characters, which is relatively short and consistent with an earnings release announcement rather than a full interim report. The presence of an investor presentation as an exhibit supports the classification but does not override the primary content. Therefore, the document is best classified as an Earnings Release (ER).
2024-05-14 English
10-Q
Interim / Quarterly Report Q1 2024
2024-05-14 English
SC 13G
Major Shareholding Notification
2024-05-11 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or updates by a company. The content includes termination of a material definitive agreement, preliminary financial condition information, and an attached investor presentation. The document does not contain full financial statements or detailed financial analysis typical of an Interim/Quarterly Report (IR) or Annual Report (10-K). The presence of an attached investor presentation (Exhibit 99.1) and the nature of the updates align with a Capital/Financing Update or Investor Presentation. However, since the main body is a Form 8-K with multiple items including a financial update and an attached presentation, the best classification is Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other categories. The document is not merely an announcement of a report but a regulatory filing with substantive content. Confidence is high due to clear identification of the form and content.
2024-05-01 English
4
Director's Dealing
2024-04-04 English
4
Director's Dealing
2024-04-04 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.